Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results
May 10, 2017 08:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - May 10, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)
Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a...
Aevi Genomic Medicine to Host Conference Call to Announce First Quarter and Discuss Recent Business Updates
May 03, 2017 08:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - May 3, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Wednesday, May 10,...
Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference
April 27, 2017 08:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Apr 27, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present...
Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
April 20, 2017 16:30 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Apr 20, 2017) -
-- Novel genetic mutations predictive of response to AEVI-001 found in approximately 10% of pediatric ADHD patients --
-- New...
Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
April 12, 2017 16:30 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Apr 12, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that results identifying a genomic subset of responders from the SAGA trial...
Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference
March 30, 2017 08:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Mar 30, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Brian D. Piper, Chief Financial Officer, will present at the 16th...
Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
March 20, 2017 07:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Mar 20, 2017) -
Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose...
Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference
March 15, 2017 08:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Mar 15, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present...
Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
March 09, 2017 07:30 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Mar 9, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)
Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be...
Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference
February 27, 2017 08:00 ET
|
Aevi Genomic Medicine, Inc.
PHILADELPHIA, PA--(Marketwired - Feb 27, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present...